Acute Myeloid Leukemia Clinical Trials

A listing of Acute Myeloid Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 274 clinical trials
A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)

-M1)." The specific subtype of acute myeloid leukemia will determine which sub-study, within this protocol, a participant will be assigned to evaluate investigational therapies or combinations with

  • 103 views
  • 23 Oct, 2022
  • 16 locations
A Phase 1b Study of JNJ-75276617 in Combination With AML Directed Therapies for Participants With Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations

The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of JNJ-75276617 in combination with AML directed therapies (dose selection) and further to evaluate

venetoclax
azacitidine
  • 0 views
  • 20 Oct, 2022
  • 9 locations
NK Cell Therapy for AML

This is a single-arm, open-label, non-randomized, multiple-dose, phase 1 dose escalation study evaluating the safety, efficacy and PK of CT101a in patients with relapsed/refractory acute myeloid

  • 0 views
  • 04 Oct, 2022
  • 1 location
A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)

This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy and PK of APG-2575 in combination with Azacitidine in the patients with AML/MPAL or MDS/CMML

  • 0 views
  • 04 Oct, 2022
  • 3 locations
Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

The investigators hypothesize that flotetuzumab for relapsed AML following allo-HCT will be safe, tolerable and may facilitate preferential immune effector cell retargeting of leukemic cells

  • 0 views
  • 07 Oct, 2022
  • 1 location
A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002)

a dose escalation which will follow an accelerated titration design (ATD). Part 2 is a dose expansion in the same relapsed/refractory (R/R) AML subtypes as in Part 1.

  • 1 views
  • 04 Oct, 2022
  • 2 locations
An Open, Single Center, Randomized Controlled Clinical Study of UCB (Cord Blood) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)

infusion after mobilization of HLA mismatched donors. Preliminary clinical studies verified that after more than 70 cases of elderly acute myeloid leukemia were treated with microtransplantation, the

  • 0 views
  • 22 Oct, 2022
  • 1 location
Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia

regrowth and relapse. Moreover, it has been experimentally shown that leukemic cells in acute myeloid leukemia patients who relapse become sensitive to glucocorticoids treatment highlighting a novel

  • 0 views
  • 04 Oct, 2022
  • 5 locations
A Phase 1B, Open-label, Global, Multicenter, Dose Determination Study to Evaluate Safety, Tolerability, and Preliminary Efficacy of CC-486 (ONUREG®) in Combination Therapy in Subjects With Acute Myeloid Leukemia (AML) (OMNIVERSE)

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-486 (ONUREG®) in combination with venetoclax in relapsed and/or refractory Acute Myeloid

azacitidine
venetoclax
  • 0 views
  • 15 Oct, 2022
  • 9 locations
Phase 1/2 Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML) That is Refractory to or Relapsed After Induction Therapy

This is a Phase 1/2, multicenter, open-label, dose-escalation study that will determine the MTD and RP2D of L-Annamycin in combination with cytarabine for the treatment of subjects with AML that

cytarabine
  • 0 views
  • 22 Oct, 2022
  • 1 location